HELIOS Klinikum Emil von Behring GmbH
- Address
- lock Available on a paid plan
Digestive System Diseases
The department is conducting studies on metastatic colorectal cancer and advanced rectal cancer, aiming to improve treatment outcomes and organ preservation.
- Trifluridine/tipiracil plus panitumumab versus bevacizumab in first‑line metastatic colorectal cancer
- Post‑resection/ablation chemotherapy for metastatic colorectal cancer
- Short‑course radiotherapy versus chemoradiotherapy with selective organ preservation in high‑risk rectal cancer
- Fruquintinib combined with Tislelizumab in microsatellite stable metastatic colorectal cancer without liver metastases
HELIOS Klinikum Emil von Behring hosts 29 active trials with 14 investigators, reflecting a strong focus on gastrointestinal oncology.
Immune System Diseases
Research includes innovative immunotherapies for lung and kidney cancers, evaluating combinations that may enhance immune response.
- Pembrolizumab plus axitinib versus sunitinib in renal cell carcinoma
- Durvalumab combined with domvanalimab after chemoradiation in unresectable stage III NSCLC
- Nivolumab and ipilimumab with chemotherapy versus chemotherapy alone in stage IV NSCLC
- LY3537982 dose‑optimization study in combination with pembrolizumab
These trials aim to test new immune‑modulating agents and assess their safety and efficacy in patients with advanced malignancies.
Neoplasms
The oncology unit focuses on a broad range of solid tumours, from lung to mesothelioma, seeking novel targeted and combination therapies.
- ALK‑positive NSCLC studies with brigatinib, alectinib, and NVL‑655
- EGFR‑mutated NSCLC treated with amivantamab plus lazertinib versus osimertinib
- KRAS G12C‑mutant NSCLC evaluated with divarasib, sotorasib, adagrasib, and pembrolizumab combinations
- Unresectable pleural mesothelioma trial comparing volrustomig plus carboplatin/pemetrexed to standard regimens
The site’s multidisciplinary team is dedicated to advancing cancer care through these diverse investigational programs.
Respiratory Tract Diseases
Studies target various lung conditions, including several subtypes of non‑small cell lung cancer and small‑cell lung cancer, to improve survival and disease control.
- Dato‑DXd monotherapy versus chemotherapy in advanced NSCLC after osimertinib
- Lurbinectedin plus atezolizumab maintenance therapy in extensive‑stage small‑cell lung cancer
- Entrectinib versus crizotinib in ROS1‑rearranged NSCLC with CNS metastases
- Inhalation therapy trial for adult bronchiectasis patients with new Pseudomonas aeruginosa infection
These trials evaluate both targeted agents and novel delivery methods to address unmet needs in respiratory oncology.
Skin and Connective Tissue Diseases
Research includes therapeutic approaches for chronic wounds and inflammatory lung disease, focusing on healing and disease modulation.
- Topical allo‑APZ2‑CVU for therapy‑resistant chronic venous ulcers
- Namilumab evaluation in chronic pulmonary sarcoidosis
- Stem‑cell therapy investigation for long‑term non‑healing venous leg ulcers
- ColiFin® therapy versus standard of care for airway colonization in bronchiectasis
The aim is to enhance wound closure rates and reduce inflammatory activity, offering new options for patients with persistent skin and connective tissue disorders.
Environment and Public Health
The institution also addresses public‑health aspects by exploring infection control and environmental factors influencing disease outcomes.
- Evaluation of ColiFin® therapy to achieve airway culture negativity in bronchiectasis
- Assessment of infection‑related outcomes in chronic lung disease trials
- Monitoring of safety signals across multiple oncology studies to inform public health policy
- Integration of real‑world data for environmental exposure analysis in cancer patients
These initiatives support broader health strategies and aim to translate clinical findings into community‑wide benefits.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 7 therapeutic areas and 15 of 78 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 77 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 11 by active trials.
lock +10 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC7trials
lock +7 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in HELIOS Klinikum Emil von Behring GmbH
lock Showing 1 of 44 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab | Merck Sharp & Dohme LLC | Phase III | Recruiting | Aug 2018 | — |
IMP list
lock Showing 1 of 78 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 14 | Unknown | 2016-09-16 | 2026-06-11 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.